key: cord-0944425-g5wts7f4 authors: Mallakpour, Shadpour; Azadi, Elham; Hussain, Chaudhery Mustansar title: Chitosan, alginate, hyaluronic acid, gums, and β-glucan as potent adjuvants and vaccine delivery systems for viral threats including SARS-CoV-2: A review date: 2021-05-25 journal: Int J Biol Macromol DOI: 10.1016/j.ijbiomac.2021.05.155 sha: c4fea7e6727b89f0ac6ca31496df7152ea530621 doc_id: 944425 cord_uid: g5wts7f4 Pathogen transmission is a widespread threat to global human health. Vaccines are very important during the outbreak of a pandemic. Destructive fractures caused by a sudden outbreak of COVID-19 have spurred vaccine production at an unprecedented rate. The strategy of an effective vaccine delivery system is opening up novel probabilities to make more immunization. Indeed, vaccination is the most successful way to prevent deaths from infectious diseases. In order to optimal immune response production or improvement in the effectiveness of vaccines, delivery systems or adjuvants are required. Natural polymers such as chitosan, alginate, hyaluronic acid, gums, and β-glucan with antiviral activity have good potential as adjuvant or delivery systems for vaccine formulation development and design vaccine delivery devices. According to the antiviral performance and immunomodulation of these biopolymers, they will play significant characters in the anti-COVID-19 field. In this mini-review, the recent progress in vaccine development by using biopolymers is presented which, provides a reference for their research on anti-COVID-19 drugs and vaccines. them or kill them. Sulfated polysaccharides with polyanionic features block the positive charge on the surface of the cell for inhibiting the adsorption of virus or invasion. Also, polysaccharides can inhibit viral transcription and replication. Furthermore, they are responsible for activating the host antiviral immunomodulatory system [7-14]. As mentioned above, natural polymers as adjuvants or immune potentiators are useful for immunogenicity improvement, sustained release of drugs, and antigen stability. These polysaccharides, directly and indirectly, exhibit antiviral effects and activities by interfering with the viral life cycle or enhancing body immunity. Therefore, these compounds are expected to have excellent application in the preparation of a vaccine for emerging and pandemic threats [15, 16] . With the onset of acute respiratory syndrome, the SARS-CoV-2 has created a unique global disorder in the health, social stability, and economies of countries. This virus has severely affected human life. So far, various compounds with antimicrobial properties such as polysaccharides and nanoparticles have been used to control the disease and provide personal protective equipment such as gowns, gloves, and masks [17] . The possible mechanism of action of polysaccharides on the virus and their anti-SARS-CoV-2 effects is seen in Fig. 1 , which shows their influence by interfering with the life cycle of the virus [13] . However, the global scientific community is studying and preparing vaccines as the most effective solution to prevent SARS-CoV-2 infection, and control and spread the COVID-19 [18] . In this minireview, the recent progress in vaccine development by using biopolymers including chitosan, alginate, hyaluronic acid, gums, and β-glucan, is presented which, provides a reference for their research on anti-SARS-CoV-2 drugs and vaccines. Chitosan and derivatives, as natural polymers with great and valuable features such as J o u r n a l P r e -p r o o f antiviral, anti-fungal, anti-bacterial, and antioxidant characteristics, affordability, biodegradability, have been applied in diverse uses like biomedical. Recently, this biopolymer was used as a potential biomacromolecule against the SARS-CoV-2 virus, preparation antiviral vaccines, and adjuvants [19, 20, [29] [30] [31] [21] [22] [23] [24] [25] [26] [27] [28] . Indeed, the virulence of this virus is mainly due to the capability of spike protein for binding to ACE2 receptors existing in the human respiratory tract and start an infection. These polymers and derivatives prevent the spike protein from binding to the ACE2 receptors and inhibit infection (Fig. 2) . Chitosan enhances cell-mediated as well as humoral immune responses. Owing to positive charge and ionic interactions with the negatively charged cell membranes, chitosan causes superior uptake via antigen-presenting cells. Likewise, by electrostatic attractions with DNA as well as antigens with negative charges, it can be applied in vaccine delivery. Till now, it has been tested as a nano-carrier to deliver antigens and raise immune responses. Also, the performance of its adjuvants can be explained in three or more mechanisms: providing a depot for the antigen to slow release, facilitating the antigen targeting to immune cell and improve phagocytosis, modulation and enhancement immune response induced by the antigen alone [19, 20, [29] [30] [31] [21] [22] [23] [24] [25] [26] [27] [28] . The hepatitis E virus is a causative agent of hepatitis, causes serious infections and risks and deaths worldwide. A safe and effective vaccine is the best way to deal with this global threat. In one study reported by Wei et al., in order to control and prevent hepatitis E infection, chitosan nanoparticles were used to prepare an effective vaccine [23] . In this study, stable chitosan/truncated capsid protein p146 nanoparticles were successfully prepared by the covalent cross-linking of chitosan and tripolyphosphate. After antigen loading, the size of the chitosan nanoparticles increased slightly to reach a 200-300 nm diameter to efficient uptake through the antigen-presenting cells. Nanoparticles with positive charge can be efficiently J o u r n a l P r e -p r o o f internalized through dendritic cells, and meaningfully stimulate the maturation of cells, signifying that delivery systems based on chitosan can act as adjuvants. Furthermore, for molecular interaction with the target cells, the surface charge has a critical role. It has been shown that the incorporation of antigen-presenting cells with cationic nanoparticles is more efficient than neutrally charged ones. So, this natural polymer was investigated as a mucosal delivery system for encapsulation of truncated capsid protein p146. Physical, chemical, cytotoxicity, and immunogenicity in mice were evaluated for this system and compared to the purified p146. Immunogenicity was analyzed by assessing cellular and humeral immune responses. The chitosan/p146 system with 200-300 nm and spherical morphology showed 65-73.9% encapsulation efficiency and 27.7-67.5% loading capacity. Additionally, the chitosan/p146 system exhibited low-cytotoxicity and a sustained-release influence. Moreover, expression levels, as well as mRNA transcription for the chitosan/p146 system, were better than purified p146, so, the fabricated nanoparticles were a vaccine candidate for potential hepatitis E. In a study by Namasivayam et al. by in-situ ionic gelation technique, hepatitis Bsurface antigen vaccine was manufactured by chitosan/polyethylene glycol nanocomposite (100-120 nm) as a harmless and efficient vaccine for improvement the immunogenicity [24] . For determination of the sustained release of antigen, an in-vitro dissolution study has been performed. The controlled release develops the temporal/spatial presentation of antigen, protects from physiological elimination, and improves patient compliance as well as quality control. By several mechanisms such as surface erosion, disintegration, diffusion, and desorption, the antigen release from the polymeric nanoparticles can take placed. In this work, the prepared nanocomposite showed advantages such as great antigen loading, remarkable stability, and release pattern, bio-compatibility, non-target effect, enhanced immunogenicity effect. By experimenting on animals, it showed no sign of toxicity and J o u r n a l P r e -p r o o f mortality. Overall, the findings showed successful preparation and the great potential of this immunizing agent for hepatitis B. Surface spike protein in the SARS-CoV-2 virus is the main feature of it and shows a critical character in infection. It allows viral entry via mediating high specificity viral attachment to the host cell surface of the ACE2 receptor. Recently, for treatment and vaccination toward COVID-19, a new idea by using chitosan-coated DNA vaccine was reported (Fig. 3) . The plasmid DNA vaccine is used as an effective vaccine to fight bacterial and viral diseases. Optimal plasmid DNA delivering to the target cell is a challenge for proper protein expression and immune response. In fact, the immunogenicity of these vaccines is low. Due to the repulsion of negatively charged phospholipids, the effectiveness of plasmid DNA vaccines is small, and they cannot cross the cell membrane. These vaccines are developed with the help of chitosan as a delivery system. This cationic polymer can be attached to a negative charge of DNA and provide an efficient means to prevent DNA vaccine from degradation. Chitosan contains several satisfactory properties for delivery DNA vaccine, for example, mucoadhesion, highly soluble, being inert as well as non-immunogenic. Also, a major site for pathogens and human contamination is the mucosal surface, so, chitosan-based DNA vaccination is highly desirable on the mucosal surface and it can effectively deliver the vaccine to the mucosal surfaces where the virus reproduces and site of viral infection. In a recent report, the utilization of inhaled plasmid DNA vaccine comprising spike protein DNA sequence of SARS-CoV-2 for treatment was stated. A 138-nanometer inhalation vaccine (similar to the SARS-CoV-2 virus) with the ability to reach deep into the lungs was reported in this work. Plasmid DNA-created spike proteins functioned for immunity creation and worked as an inexpensive antagonist toward attachment of coronavirus host cells [28] . Another natural polysaccharide with great features and applications [32] is alginate. Recently this polymer was used for combination viral such as SARS-CoV-2 [21, 33] . Hepatitis A is a liver disease caused by a virus that passes through the fecal-oral route. This disease is preventable and vaccination is the best way to prevent it. The disease is prevalent in areas that are poor sanitary conditions and economy. This infection is common in people under 10 years of age. This infection rarely causes death and its severity increases with age. To overcome the high cost and improve the immune system, adjuvants are used. In most countries, formaldehyde-inactivated vaccines as efficient vaccines for this disease are accessible. But, it has disadvantages such as the safety and efficacy of vaccines based on this substance. So, there is an urgent need to find a safe and effective alternative for improving vaccine release and developing immune responses. An ideal adjuvant creates a balanced Th1 and Th2 immune response. Both of these are necessary to protect against viral infections. Th1 and Th2 are related to cell-mediated immunity and humoral immune response, respectively. In a recent study, an effective adjuvant for Hepatitis A vaccine was used and compared with traditional alum adjuvant [34] . The immune response of vaccines was J o u r n a l P r e -p r o o f evaluated. Indeed, in this work, immune responses to alum-, chitosan-, and alginate/chitosanbased vaccine were assessed in mice. Humoral and cellular immune responses were improved by using alginate-coated chitosan nanoparticles. After 28 days from vaccinations, splenocyte stimulation was evaluated. Vaccines prepared with the help of alginate/chitosan improved immunity via the development of seroconversion rate (100%), antibodies level of hepatitis A, as well as the splenocytes proliferation. The IgG level for the alginate/chitosan-based vaccine significantly was enhanced in comparison with other groups. Besides, antibody levels were increased in the presence of chitosan compared to alum. Hepatitis B viral infection is a serious risk for healthcare workers. As mentioned, the alum-based vaccine has limitations, including poor response and cold-sensitive suspension. Alum also causes inflammation and local reactions at the injection site. The hepatitis vaccine is made from pure recombinant proteins, which unfortunately show little safety. Therefore, adjuvants are used to improving safety. So, AbdelAllah et al. used alginate adjuvant systems for better immunogenic and permitting to reduce in cost as well as dose [35] . Immunogenic response, as well as safety of the prepared adjuvants-based vaccine, were examined, compared with commercially available adjuvants, and good results were obtained. Also, vaccine surface antigen adjuvanted with chitosan and alginate and a combination of them were tested in a mouse model. Mice were immunized with the subcutaneous vaccine and compared with control models without adjuvant. Seroconversion rate, serum antibody, IL-4, as well as IFN-levels were evaluated, and the outcomes exhibited higher immunogenic response for alginate/chitosan-based vaccine compared to alum-adjuvanted [36] . Chitosan and alginate are non-toxic and non-irritating natural polymers used in clinical trials and have advantages including outstanding immune stimulation, respectable tolerability, being safe and cheap, and positive clinical results. Considering the outcomes, the alginate/chitosan provided a meaningfully higher J o u r n a l P r e -p r o o f immunogenic response in comparison with controls. Because influenza epidemics kill thousands around the world, so, improving the immunogenicity and performance of the vaccines is of great importance. In one study by Dehghan and co-workers, alginate nanoparticles were fabricated via ionic gelation technique and then, the influenza vaccine and adjuvants were incorporated into alginate nanoparticles [37] . Physico-chemical, as well as biological investigations, exhibited no influence of the encapsulation process on the construction and chemistry of protein. After injection, immune responses (humoral and cellular immune responses) were assessed in rabbits'nostrils. Based on the obtained data, after a combination of CpG ODN (efficient adjuvant) with influenza virus, a strong humoral and cellular immune response was observed. Also, in another study, the hepatitis B vaccine and CpG ODN were inserted into alginate-coated chitosan to improve the immune response after the oral vaccination. High immunogenicity was observed after the injection. Higher values of the CD69 expression in CD4+ and CD8+ T-lymphocytes and lower values of this marker in B lymphocytes were observed [38] . For mucosal vaccine delivery, microfold and dendritic cells in lymphoid tissue can better take nanoparticulate antigens. Chitosan nanoparticles and derivatives (trimethylchitosan) are a proper carrier/adjuvant for this aim. By using anionic polymer such as alginate, immunostimulatory features and stability can enhance. So, in a study, inactivated PR8 influenza virus was inserted into chitosan and trimethylchitosan nanoparticles via direct virus coating. After nasal immunizations, the elicited IgG2a and IgG1 antibody titers in PR8/chitosan formulation were higher than PR8/trimethylchitosan. With coating, these formulations with alginate, Th1-type immune response (IgG2a/IgG1 ratio) for PR8/trimethylchitosan/alginate was higher than PR8/chitosan/alginate. Based on the outcomes, PR8/trimethylchitosan/alginate formulation was considered as an efficient carrier for nasal vaccines [15] . Influenza viruses belong to the RNA virus family and are classified into three types (A, B, C) according to their antigenicity. Injectable influenza vaccines, which are used in the clinic, produce immunoglobulin G (IgG) in the blood and protect against viral infections. Indeed, one of the most effective ways to combat influenza epidemics is mucosal vaccination, which releases immunoglobulin A (IgA) on the mucosa along with the induction of J o u r n a l P r e -p r o o f immunoglobulin G (IgG) in the blood. In a study by Tanishita et al., hyaluronic acid was modified with tetraglycine-L-octaarginine, and then, mucosal adjuvant by using modified hyaluronic acid was prepared [40] . This research team performed the heterologous influenza A virus challenge to confirm the performance of this biopolymer as an adjuvant with crossprotective capacities. Immunoglobin is expected to prevent host infection. After nasal inoculation of inactivated viruses into mice, and then, exposure to infectious viruses, severe weight loss was observed. In fact, in the presence and absence of this biopolymer, mice were inoculated with inactivated viral particles. In mice inoculated with viral antigens and modified hyaluronic acid, viral infectious symptoms were difficult to observe due to the high induction of immunoglobulins that can interact with viruses. Based on the results, this polysaccharide derivative enables the host to increase immunity and the ability to protect against viral infection. So, this study showed that this biopolymer is a good candidate mucosal adjuvant to protect against viral infection. Hyaluronic acid, a biodegradable biopolymer in the glycosaminoglycan category, is an extracellular matrix compound that is distributed throughout the body and degrades by enzymes (hyaluronidases). It is widely used in medicine as well as cosmetics. On the other hand, the conversion of the non-degradable platform into a degradable form is essential for clinical use. In another study, degradable cell-penetrating peptides were prepared to employ hyaluronic acid derivatives. To circumvent the latent risk of toxicity caused by the accumulation of doctaarginine-linked poly(N-vinylacetamide-co-acrylic acid) in the human body, the hyaluronic acid-based platform was prepared. In-vitro examines showed low toxicity of the hyaluronic acid derivative compared to poly(N-vinylacetamide-co-acrylic acid) derivatives. Overall, this study confirmed the safety of hyaluronic acid-based adjuvant for mucosal influenza vaccination [41] . In a study by Choi et al. by using hyaluronic acid and polycaprolactone, microneedles J o u r n a l P r e -p r o o f (insertion-responsive microneedles) for transcutaneous influenza vaccination were prepared and the performance of them was evaluated (Fig. 6A) [42] . Vaccine antigens were covered on hyaluronic acid tips through fast freezing the tips before the dip-coating process. Ex-vivo experiments have shown that microneedles can penetrate the skin without fracture and release the drug properly. As can be observed in figure, vaccine-covered tips are easily removed from the base as soon as they are injected (Fig. 6B ). Compounds used as vaccine adjuvants are used to improve antigen immunogenicity. The most commonly used adjuvants approved by the Food and Drug Administration are aluminum-based salts. The formulation of new adjuvants is in progress. Nucleic acids, emulsions, or bacterial products have revealed the ability as an adjuvant, but preclinical trials exhibited not safe for human use. In fact, natural polymers play significant characters in the immune response and the creation of biocompatible formulations for vaccines. Natural polymers derived from plants and microbes are used as an adjuvant in vaccination. Xanthan gum, a natural polymer made from plants that has adhesive properties, is used in the pharmaceutical industry as a viscous. So far, it has been proven that this natural polymer can increase the immunity of recombinant antigens and make them resistant to pathogens. It has been used in bio-adhesive formulations for intranasal influenza virus immunizations. In a study, Schuch and coworkers studied the generated immune response by Xanthan adjuvant by using ovalbumin antigen. The induced immune response by this polymer associated with antigen in terms of antibody production and levels of IFN-was investigated. Also, the cytotoxicity of this natural polymer in rat fetal fibroblast cells was also investigated in-vitro and according to the results, no cytotoxicity was observed. Mice immunized with xanthanantigen showed higher antibody IgG1 production compared to controls [43] . Adjuvants can be synthetic or natural components. These adjuvants associated with antigen can boost the immune system. Therefore, these adjuvants can reduce vaccine doses as well as antigen amounts. Eventually, the cost of producing the vaccine will be reduced. In a study, Silveira et the relationship between probiotics (partially hydrolyzed guar gum PHGG) and the onset of influenza in hospitalized patients was studied. In this study, patients were divided into two groups: One group used PHGG consistently and the other group did not. According to the results of the analyses, people who got the influenza infection were in the group that did not use PHGG. These results showed that this PHGG has an effect on the intestinal environment and reduces the incidence of influenza [45] . [48] . Blood samples were collected and analyzed before and after the first vaccination at selected intervals. The lack of imbalance in haematological indicated the safety of delivery agents for vaccination of Newcastle disease vaccine. As mentioned, vaccination is one of the utmost efficient strategies for preventing infectious diseases via the production of immunogenic antibodies. Vaccines and additives are effective in inducing cytotoxic lymphocytes as well as T cells, which are needed for fighting infection. A DNA vaccine is a known treatment applicant for the chronic hepatitis B vaccine, which, elicits a strong immune response in the host cell. For some pathogens, a vaccine that provides long-term immunity and the protective effect is challenging. β-glucan is a natural J o u r n a l P r e -p r o o f polymer found in the cell wall of bacteria and fungi and has been used as an adjuvant and vaccine development [49] . In immune modulation, as a pathogen-associated molecular pattern, β-glucan is recognized via transmembrane pattern recognition receptors. With the formation binding of Glucan-receptors phagocytosis of the glucan shell, the release of proinflammatory cytokines, chemokines, anti-microbial proteins have happened. In a study, Borges et al. showed the potential performance of glucan for preparation of delivery nanosystem as DNA vaccination platform [3] . Currently, approved additives are not able to induce a cellular immune response. A proper vaccine adjuvant has many characteristics; as immunopotentiator for simulation of antigen-presenting cells for T cells activation, carrier for enhancement the uptake, sustained processing and antigens cytosolic delivery, being safe, as well as available. Aminated βglucan (AβG) presents these roles, so, in a recent study, AβG nanoparticles were fabricated via ionic complexation technique. Antigens were encapsulated in it (AβG -Ovalbumin). Indeed, AβG acted as antigen-presenting cells targeted carrier and immunopotentiator. They were cross-linked with CpG-oligodeoxynucleotides as cross-linker and immunopotentiator (Fig. 7) . After that, the adjuvant performance of these particles was estimated by in-vivo and in-vitro examinations. Based on the outcomes, the prepared particles showed strong immune responses (humoral and cellular) without toxicity. The strong adjuvant performance of the prepared particles toward infectious diseases was due to the synergistic impacts of aminated β-glucan and CpG-oligodeoxynucleotides [50] . After subcutaneous injection into mice with hepatitis B antigen, an increase in antibody was observed for all particles. However, just glucan particles could induce strong cytokinemediated immunity. Indeed, glucan particles showed great performance as adjuvant and antiviral immunity components for the hepatitis B vaccine [49] . Also, in another study, a research team by combining natural polymers chitosan and glucan, prepared an adjuvant and studied their properties. For this aim, via the precipitation process, (precipitation of chitosan into an alkaline solution of glucan and genipin cross-link), chitosan:β-glucan particles were prepared. The prepared particles had benefits such as low cytotoxicity and high antigen loading. According to Mice vaccination studies, chitosan and chitosan: glucan particles showed a good adjuvant effect on hepatitis B antigen, however, the antibodies produced by chitosan: glucan was higher than chitosan particles [1] . The global scientific community is studying and preparing vaccines as the most effective solution to prevent SARS-CoV-2 infection, and control and spread the COVID-19. As stated in this study and summarized in Table 1 , natural polymers such as chitosan, alginate, gums, and so on have good potential for developing safe and new vaccines to prevent the spread of infectious diseases, including COVID-19 disease, due to their antiviral performance, non-toxic, and biocompatibility features. This mini-review presented the recent development in vaccine progress by using natural polymers which, provides a reference for their research on anti-COVID-19 drugs and vaccines. The authors declare that they have no conflict of interest. [7] A.L.Z. Lee, C. Yang Fig. 3 . A, DNA vaccine induction of humoral and cellular mucosal immune response. 1 transfection of epithelial cell 2 expression of S1 protein, 3 secretion of S1 protein, 4 S1 protein taken up by M cells, 5 transported to immune cells with 6 uptake by dendritic cells J o u r n a l P r e -p r o o f and MHC II antigen presentation to T-cells with subsequent draining into lymph node stimulating humoral response. 8. MHC 1 presentation stimulated cytotoxic lymphocyte response. B, DNA vaccine treatment with secreted S1 spike protein acting as a competitive antagonist by interfering with the coronavirus binding to ACE2 receptors. 1 transfected cell 2.expression of S1 protein, 3 secretion of the S1 protein, and 4 ACE2 receptor blockade by S1 protein preventing SARS-CoV-2 from binding to ACE2 receptor [28] Fig. 4. Schematic representation of chitosan based nanoparticle used for delivering bacterial and viral vaccine to mucosal sites of poultry and pigs, and the vaccine induced mucosal immune responses [31] J o u r n a l P r e -p r o o f Schematic illustration of the proposed dual targeting aminated b-glucan nanoparticles for induction of antigen specific immunity. Firstly, b-glucan was aminated, and then the nanoparticles were made from aminated b-glucan, CpG-OND and OVA by ionic complexation method. Having been vaccinated, the nanoparticles were internalized by APCs, and the uptake of the nanoparticles was mediated by dectin-1. Then, the nanoparticles were unfolded in acidic environment of endosome/lysosome, resulting in CpG-OND and OVA released from the nanoparticles. CpG-OND was recognized by TLR9 on endosome/lysosome. OVA in endosome/lysosome was loaded into MHC II where it can be presented to CD4+ through specific interaction with TCR on CD4+, inducing Th1 and Th2 responses. Th1 responses further promoted CTL responses. The OVA delivered to cytosol was loaded into MHC I where it can be presented to CD8+ through specific interaction with TCR on CD8+, inducing CTL responses. Synergistic stimulation of APCs by dectin-1 and TLR9 resulted in upregulation of Th1 cytokines and chemokines. Th1 cells and CTLs induced cellular immunity. Meanwhile, Th2 cells induced humoral immunity. The specific interaction of costimulatory molecules (CD80/CD86) on APCs with CD28 on CD4+/CD8+ was essential for induction of antigen specific immunity, and the expression levels of costimulatory molecules were also enhanced by synergistic stimulation of APCs by dectin-1 and TLR9 [50] . Chitosan:β-glucan particles as a new adjuvant for the hepatitis B antigen A novel vaccine platform using glucan particles for induction of protective responses against Francisella tularensis and other pathogens Polymeric nanoengineered HBsAg DNA vaccine designed in combination with β-glucan Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice Cationic Poly(Amino Acid) Vaccine Adjuvant for Promoting Both Cell-Mediated and Humoral Immunity Against Influenza Virus Adjuvant potency of astragaloside vii embedded cholesterol nanoparticles for H3N2 influenza vaccine Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization Fabrication and characterization of DDAB/PLA-alginate composite microcapsules as single-shot vaccine Antibacterial agents applied as antivirals in textilebased PPE: a narrative review Engineering antiviral vaccines Chitosan/carbon nanotube hybrids: Recent progress and achievements for industrial applications Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: A plausible molecule against SARS-CoV-2? Protection, disinfection, and immunization for healthcare during the COVID-19 pandemic: Role of natural and synthetic macromolecules Hydroxyapatite mineralization of chitosan-tragacanth blend/ZnO/Ag nanocomposite films with enhanced antibacterial activity Chitosan Nanoparticles Loaded with Truncated ORF2 Protein as an Oral Vaccine Candidate against Hepatitis E HBsAg) vaccine fabricated chitosan-polyethylene glycol nanocomposite (HBsAg-CS-PEG-NC) preparation, immunogenicity, controlled release pattern, biocompatibility or non-target toxicity Preparation and immunological evaluation of inactivated avian influenza virus vaccine encapsulated in chitosan nanoparticles Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant Lipopolysaccharide derived alginate coated Hepatitis B antigen loaded chitosan nanoparticles for oral mucosal immunization A novel concept for treatment and vaccination against Covid-19 with an inhaled chitosan-coated DNA vaccine encoding spike protein portion Novel approach to improve vaccine immunogenicity: Mannosylated chitosan nanoparticles loaded with recombinant hepatitis B antigen as a targeted vaccine delivery system Chitosan, hydroxypropyltrimethyl ammonium chloride chitosan and sulfated chitosan nanoparticles as adjuvants for inactivated Newcastle disease vaccine Chitosan Nanoparticle Based Mucosal Vaccines Delivered Against Infectious Diseases of Poultry and Pigs Adsorptive performance of alginate/carbon nanotube-carbon dot-magnesium fluorohydroxyapatite hydrogel for methylene blue-contaminated water Antiviral activity of sulfated polysaccharides from marine algae and its application in combating COVID-19: Mini review Alginate-coated chitosan nanoparticles act as effective adjuvant for hepatitis A vaccine in mice Alginate Combinations Are Alternative, Efficient, and Safe Natural Adjuvant Systems for Hepatitis B Vaccine in Mouse Model, Evidence-Based Complement Alginate-chitosan microcapsules improve vaccine potential of gammairradiated Listeria monocytogenes against listeriosis in murine model Preparation, characterization and immunological evaluation of alginate nanoparticles loaded with whole inactivated influenza virus: Dry powder formulation for nasal immunization in rabbits Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus Cross-Protective Abilities of Hyaluronic Acid Modified with Tetraglycine-l -octaarginine as a Mucosal Adjuvant against Infection with Heterologous Influenza Viruses Biodegradable Hyaluronic Acid Modified with Tetraglycine-l -octaarginine as a Safe Adjuvant for Mucosal Vaccination Insertion-responsive microneedles for rapid intradermal delivery of canine influenza vaccine The Use of Xanthan Gum as Vaccine Adjuvant: An Evaluation of Immunostimulatory Potential in BALB/c Mice and Cytotoxicity In Vitro Biopolymer Xanthan: A New Adjuvant for DNA Vaccines The effect of partially hydrolyzed guar gum on preventing influenza infection Clinical and pathological responses of broilers to ocular vaccination using plant gum delivery and challenge with infectious bursal disease virus Evaluation of mucoadhesive property and the effect of Boswellia carteri gum on intranasal vaccination against small ruminant morbillivirus infection (PPR) Haematological Changes Associated with Newcastle Disease Vaccination in Chickens Using Gums from Cedrela odorata and Khaya senegalensis as Delivery Agents Glucan Particles Are a Powerful Adjuvant for the HBsAg, Favoring Antiviral Immunity Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses Fig. 1. The proposed mechanisms of polysaccharides anti-SARS-CoV-2 We are immensely grateful for financial support from the Research Affairs Division of [23]